IL281023A - Tetrahydropyridopyrimidine derivatives as AHR modulators - Google Patents

Tetrahydropyridopyrimidine derivatives as AHR modulators

Info

Publication number
IL281023A
IL281023A IL281023A IL28102321A IL281023A IL 281023 A IL281023 A IL 281023A IL 281023 A IL281023 A IL 281023A IL 28102321 A IL28102321 A IL 28102321A IL 281023 A IL281023 A IL 281023A
Authority
IL
Israel
Prior art keywords
tetrahydropyridopyrimidine
derivatives
ahr modulators
ahr
modulators
Prior art date
Application number
IL281023A
Other languages
English (en)
Hebrew (he)
Original Assignee
Jaguahr Therapeutics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jaguahr Therapeutics Pte Ltd filed Critical Jaguahr Therapeutics Pte Ltd
Publication of IL281023A publication Critical patent/IL281023A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL281023A 2018-08-24 2021-02-22 Tetrahydropyridopyrimidine derivatives as AHR modulators IL281023A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201807244X 2018-08-24
PCT/EP2019/072641 WO2020039093A1 (en) 2018-08-24 2019-08-23 Tetrahydropyridopyrimidine derivatives as ahr modulators

Publications (1)

Publication Number Publication Date
IL281023A true IL281023A (en) 2021-04-29

Family

ID=67982013

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281023A IL281023A (en) 2018-08-24 2021-02-22 Tetrahydropyridopyrimidine derivatives as AHR modulators

Country Status (14)

Country Link
US (1) US12221439B2 (https=)
EP (1) EP3841102B1 (https=)
JP (1) JP2021535213A (https=)
KR (1) KR20210049135A (https=)
CN (1) CN112739698A (https=)
AU (1) AU2019323714A1 (https=)
BR (1) BR112021003529A2 (https=)
CA (1) CA3110402A1 (https=)
IL (1) IL281023A (https=)
MX (1) MX2021002215A (https=)
PH (1) PH12021550382A1 (https=)
SG (1) SG11202101441SA (https=)
WO (1) WO2020039093A1 (https=)
ZA (1) ZA202100931B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
WO2021210970A1 (en) * 2020-04-17 2021-10-21 Dong-A St Co., Ltd. Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ZA200601859B (en) 2003-08-05 2008-03-26 Vertex Pharma Condensed pyrimidine compounds as inhibitors of voltagegated ion channels
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
MY159230A (en) 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8691827B2 (en) 2009-08-17 2014-04-08 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
BR112013002079B1 (pt) 2010-07-27 2021-09-14 Trustees Of Boston University Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
WO2016154110A1 (en) * 2015-03-20 2016-09-29 Cleave Biosciences, Inc. Companion diagnostic for p97 inhibitor therapy and methods of use thereof
CA3025227A1 (en) 2016-05-25 2017-11-30 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling

Also Published As

Publication number Publication date
CA3110402A1 (en) 2020-02-27
WO2020039093A1 (en) 2020-02-27
EP3841102A1 (en) 2021-06-30
JP2021535213A (ja) 2021-12-16
US20210332041A1 (en) 2021-10-28
ZA202100931B (en) 2021-10-27
EP3841102B1 (en) 2022-09-14
MX2021002215A (es) 2021-07-15
CN112739698A (zh) 2021-04-30
KR20210049135A (ko) 2021-05-04
BR112021003529A2 (pt) 2021-05-18
AU2019323714A1 (en) 2021-03-25
US12221439B2 (en) 2025-02-11
PH12021550382A1 (en) 2021-12-13
SG11202101441SA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
IL292156A (en) Transduced azacils as trmp8 modulators
ZA201906104B (en) Substituted imidazo-quinolines as nlrp3 modulators
IL281023A (en) Tetrahydropyridopyrimidine derivatives as AHR modulators
IL290153A (en) Tetrahydroquinolinone compounds are installed such as gamma modulators
PL3743406T3 (pl) Modulatory tmem16a
GB2576056B (en) Modulators
IL283990A (en) Modified oxopyridine derivatives
DK3749669T6 (da) Ahr-modulatorer
SG11202101499UA (en) Heterocyclic compounds as ahr modulators
GB201704739D0 (en) Optical modulator
SG11202012594RA (en) Spirochromane derivatives
LT3796975T (lt) Sulfonilaminobenzamido dariniai
GB2585587B (en) Modulators
HUE062256T2 (hu) Dihidrokromén-származékok
HK40042159A (zh) Ahr调节剂
GB201806948D0 (en) Derivatives
GB2571429B (en) Optical modulator